key: cord-0826137-3dbai74t
authors: Trigueros, M.; Pradenas, E.; Palacin, D.; Avila-Nieto, C.; Trinite, B.; Bonet-Simo, J. M.; Isnard, M.; Moreno, N.; Marfil, S.; Rovirosa, C.; Puig, T.; Grau, E.; Chamorro, A.; Martinez, A.; Toledo, R.; Font, M.; Ara, J.; Carrillo, J.; Mateu, L.; Blanco, J.; Clotet, B.; Prat, N.; Massanella, M.
title: Limited immune responses after three months of BNT162b2 vaccine in SARS-CoV-2 uninfected elders living in long-term care facilities
date: 2021-11-21
journal: nan
DOI: 10.1101/2021.11.18.21266502
sha: be0f073f9debc8ff2f69ab05085ce7fd7efc1470
doc_id: 826137
cord_uid: 3dbai74t

Background: SARS-CoV-2 vaccination is the most effective strategy to protect elders living in long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses are less effective in older adults. Here, we characterized the humoral responses following 3 months after mRNA/BNT162b2 vaccine in institutionalized elders. Methods: Plasma levels of specific SARS-CoV-2 total IgG, IgM and IgA antibodies were measured before and 3 months after vaccination in elders living in LTCF. Neutralization capacity was assessed in a pseudovirus neutralization assay against WH1 (original) and B.1.617.2/Delta variants. A group of younger adults was used as reference group. Results: Three months after vaccination, uninfected-elders presented reduced specific SARS-CoV-2 IgG levels and significantly lower neutralization capacity against the WH1 and Delta virus compared to vaccinated uninfected younger individuals. In contrast, COVID-19 recovered elders showed significantly higher specific SARS-CoV-2 IgG levels after vaccination than younger counterparts, while showing similar neutralization capacity against WH1 virus and increased neutralization capacity against Delta variant. Despite previously infected elders elicit potent cross-reactive immune responses similarly to younger individuals, higher quantities of specific SARS-CoV-2 IgG antibodies are required to reach the same levels of neutralization. Conclusions: While hybrid immunity seems to be active in previously infected elders after three months from mRNA/BNT162b2 vaccination, humoral immune responses are diminished in COVID-19 uninfected vaccinated residents living in LTCF. These results suggests that a vaccine booster dose should be prioritized for this particularly vulnerable population.

Older adults have been disproportionately affected by the Coronavirus Disease 2019 (COVID- 19) pandemic. Elders are more prone to a severe infection and over 95% of COVID-19-related mortality occurred in the population over 60 years of age [1] . Among them, residents from long-term care facilities (LTCF), who live in a congregate setting (with increased risk of transmission and infection) showed higher mortality rates than the general population of the same age [2, 3] . Therefore, vaccination of residents from LTCF against SARS-CoV-2 has been a priority in most countries. SARS-CoV-2 vaccines are currently widely available in Europe, but we are still facing several months of continuous new infections and new circulating variants of concern (VOC). Indeed, virus outbreaks have been described in nursing homes during summer 2021 with B.1.617.2/Delta variant, despite the high vaccination rates among residents and healthcare professionals [4] .

Currently available COVID-19 vaccines have shown to be safe and are able to generate an effective humoral and cellular immunity [5] [6] [7] [8] , but these studies have been performed including mainly young or middle-age healthy adults. Limited studies have evaluated the immune responses generated in elders living in LTCF [9] [10] [11] [12] [13] , and most of them studied short term immune responses (several weeks after vaccination). Ageing is associated with an immunosenescent phenotype characterized by a progressive increase of a proinflammatory state and, a diminished immune response to pathogens and vaccines [14] . Therefore, there is an urgent need to determine the quality and the duration of immune responses of the elderly population, which could be very useful for designing specific SARS-CoV-2 vaccination calendars adapted to their immune needs.

To better understand how anti-SARS-CoV-2 humoral responses is triggered in the elderly population, we performed a prospective study to evaluate the anti-SARS-CoV-2 humoral response elicited after COVID-19 vaccination in both residents living in LTCF that have recovered from a previous SARS-CoV-2 infection (N=82) and SARS-CoV-2-uninfected individuals (N=16). The humoral response against SARS-CoV-2 was evaluated before and after 3 months of administration of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11. 18.21266502 doi: medRxiv preprint Humoral responses of elders were compared to a younger population, and a functional neutralization assay was performed against the WH1 virus and the Delta variant.

Cohorts' description A total of 98 residents from three LTCF from the Northern are of Barcelona (Spain) were included in the prospective observational CoronAVI@S study (Table 1) For comparing our data with a younger population with less comorbidities, we selected a total of 110 infected participants (Table 2 ) and 51 individuals (32 infected and 16 uninfected individuals, Table 3 ), for pre-vaccine and post vaccine comparisons, respectively from the KING cohort extension. The age range of selected participants were between 22 and 64 years. Blood samples of pre-vaccine were matched with CoronAVI@S study by time post-SARS-CoV-2 infection (6 months). Post-vaccine samples were selected among individuals vaccinated also with BNT16b2 (Pfizer-BioNTech) and blood samples were obtained a median of 3 months after complete vaccination schedule. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint and HUGTiP/PI-20-217). All participants provided written informed consent before inclusion.

The presence of anti-SARS-CoV-2 antibodies against S2+RBD or NP in plasma samples was evaluated using an in-house developed sandwich-ELISA, as previously described [15] . The specific signal for each antigen was calculated after subtracting the background signal obtained for each sample in antigen-free wells. Values are plotted into the standard curve. Pseudovirus neutralization assay. Neutralization assay was performed using SARS-CoV-2.Sct∆19 WH1 and B.1.617.2/Delta pseudovirus as previously described [16, 17] . The lower limit of detection was 60 and the upper limit was 14,580 (reciprocal dilution). The ID50 (the reciprocal dilution inhibiting 50% of the infection) was calculated by plotting and fitting the log of plasma dilution vs. response to a 4-parameter equation. See supplemental material. Statistics Continuous variables were described using medians and the interquartile range (IQR, defined by the 25th and 75th percentiles), whereas categorical factors were reported as percentages over available data. Quantitative variables were compared using the Mann-Whitney test and percentages using the chi-squared test for comparison between groups, Wilcolxon for paired tests and Kruskal-Wallis test for comparison between age ranges. Analyses were performed with Prism 9.1.2 (GraphPad Software). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint

A total of 98 residents from three LTCF in the Northern area of Barcelona (Spain) were included in the prospective observational CoronAVI@S study. All participants were >65 years, with 90% of the individuals belonging to the moderate to high risk groups using GMA (Adjusted Morbidity Group) [18] . Most common chronic pathologies included hypertension (62%), arthritis (40%), dementia (38%) or diabetes (33%). Individuals were tested by RT-PCR during LTCF outbreak from March to June 2020.

Serologic and PCR tests before vaccination revealed that 84% resident included in the study suffered from previous SARS-CoV-2 infection. Previously infected residents (n=82) had a median age of 87 years and were 80% female, whereas uninfected residents before vaccination (n=16) had a median age of 79 years and were 50% female. Additional characteristics of the participants at enrolment are shown in Table 1 .

We took advantage of the national vaccination plan in LTCF to evaluate the immune responses generated by the BNT16b2 (Pfizer-BioNTech). Only one uninfected resident was infected with SARS-CoV-2 after vaccination (confirmed by NP-serology and RT-PCR), developing a mild COVID-19. This individual is shown in red in all graphs, and excluded from statistical analysis.

We first evaluated the impact of vaccination in the levels of circulating specific SARS-CoV-2 antibodies in elders living in LTCF. The levels of SARS-CoV-2 specific IgG, IgA and IgM antibodies were significantly higher in individuals who were infected prior vaccination compared to their uninfected counterparts (p<0.0001 in all cases, Figure 1A ). There was a significant increase of all isotypes of immunoglobulins between pre-and post-vaccine samples in infected elders Of note, the individual who got infected after vaccination showed similar levels of specific SARS-CoV-2 antibodies than the infected and vaccinated group. We then evaluated the levels of SARS-CoV-2 specific IgG antibodies induced after vaccination across age groups. We is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint observed higher levels of IgG antibodies in older groups (≥65 years) previously infected compared to younger individuals ( Figure 1B , Anova p<0.001, and r= 0.41, p<0.001, Supplementary Figure 2C ). To determine if the higher levels of virus-specific IgG antibodies in infected elders after vaccination was related to the vaccine or to the natural infection, we evaluated specific IgG antibodies before vaccination across ages (Supplementary Figure 2D) .

We determined that infected residents after six months from infection (and prior vaccination) showed already higher levels of SARS-CoV-2 IgG antibodies compared to the younger population (Anova p<0.001). In contrast, the levels of circulating specific SARS-CoV-2 IgG antibodies in uninfected vaccinated subjects tended to decrease across age groups (Anova p =0.06, Figure 1B ), and negatively correlated with age (r=-0.72, p<0.001, Supplementary Figure   2C ). The levels of SARS-CoV-2 specific IgG antibodies were significantly decreased already in individuals between 45 and 64 years old when comparing infected and uninfected group prior vaccination (p=0.007), and this difference was maintained in the older age groups (p<0.001 in all cases, Figure 1B ). These results highlighted some differences in antibody production between infected and uninfected individuals, being only the uninfected younger population able to produce similar levels of SARS-CoV-2 antibodies to their infected counterparts.

Neutralization capacity against original WH1 virus All residents were assayed for their plasma neutralization capacity against the Wuhan-Hu-1 (WH1) sequence in a validated pseudovirus assay [16, 17] . SARS-CoV-2 vaccination increased the titers of antibodies with neutralizing capacity in infected and uninfected elders (p<0.0001 in both cases, Figure 1C ), being the neutralization titers significantly higher in individuals with a previous history of SARS-CoV-2 infection compared to the uninfected counterparts (p<0.0001). For the infected population, there was a median fold increase of 18.7 [9.3-44.8] between pre-vaccine sample compared to post-vaccination sample. Of note, the resident who was infected after vaccination showed similar titers of neutralizing antibodies as the infected group after vaccination. We then compared the plasma neutralization capacity between residents and younger individuals, observing that previously infected subjects showed similar levels of neutralization independently of age (Anova p=0.12, Figure 1D and Supplementary Figure 2E ). We hypothesized that the neutralization response after natural infection reached a similar plateau in recovered elders than younger subjects, therefore similar levels of neutralization were reached in both groups after vaccination. For that, we compared the . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint plasma neutralization capacity before vaccination between older and younger individuals after six months from SARS-CoV-2 infection. Surprisingly, the neutralization titers were significantly lower in elders compared to younger after six months from infection (Anova p<0.001, Supplementary Figure 2F ). These differences were not related to the severity of COVID-19, since no differences were observed in elders with mild or severe disease (Supplementary Figure 2G) . These results suggest a greater boost of humoral responses in infected elders after vaccination compared to the younger group. In contrast, uninfected vaccinated subgroups showed sequential decrease of neutralization titers across ages (Anova p=0.001 Figure 1D and Supplementary Figure 2H ). Indeed, age was only negatively correlated with plasma neutralization capacity in the uninfected group (r=-0.63, p<0.001; Figure 1E ). Overall, these results suggest that uninfected older adults show lower titers of neutralizing antibodies and might be at higher risk of infection than previously infected individuals of the same age.

We then evaluated the proportion of effective neutralizing antibodies among the total SARS-CoV-2 specific IgG, calculated as the ratio of plasma neutralization titer to total SARS-CoV-2 IgG antibodies. We observed a reduction of this ratio in infected elders compared to their younger counterparts ( Figure 1F , p<0.001), suggesting low functionality of antibodies in elders, where high levels of circulating SARS-CoV-2 IgG are required to reach protection. In contrast, no differences were found between uninfected and vaccinated younger and older adults ( Figure   1C ). These results suggest that mRNA vaccine induce effective neutralizing antibodies in elders, but at lower levels.

Neutralization capacity against Delta variant Given our observation that uninfected LTCF residents aged ≥65 years had lower neutralization responses, following complete vaccination schedule than younger individuals, we hypothesized that this particular group could experience lower neutralizing responses against the VOC B.1.617.2/Delta, which has been the main variant circulating in Spain since July 2021.

Indeed, we found a significant decrease in the plasma neutralization capacity of Delta VOC is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint In this study, we have demonstrated that uninfected residents after three months from COVID-19 vaccination showed limited neutralization responses compared to the younger uninfected individuals, putting the uninfected elder population at higher risk. Vaccination with two doses of BNT162b2 of uninfected LTCF residents has been shown to reduce the risk of infection by 90%, and more than 95% in COVID-19 related hospital admission and mortality for up to 5 months [19] . These results combined with ours suggest that uninfected elders may develop a memory response, which protect them in case of a new infection. However, the low levels of circulating neutralizing antibodies after three months highlight the need of further studies to assess the long-term effectiveness of SARS-CoV-2 vaccines, and may suggest that this specific subgroup may benefit from a boost vaccine [20] . Of note, the resident who got infected after vaccination in our study, clearly show a boost of neutralization responses to the levels of the infected groups after vaccination and developed a mild COVID-19.

Importantly, previously infected elders have developed a particularly potent immune responses to COVID-19 vaccines, similar to younger individuals [10, 12, 13, 21] . Our results suggest that the combination of natural and vaccine-generated immunity, known as hybrid immunity [22] , elicit a larger than expected immune responses even in elders, despite a high degree of immunosenescence. It has been recently shown that hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants [23] . Elders show higher capacity to neutralize is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint more resistant variants (i.e., B.1.617.2/Delta) than younger individuals, being the hybrid immunity a benefit for this recovered population.

Our results demonstrate that natural infection (pre-vaccine) generates higher virus-specific IgG antibodies in elders compared to the younger population. In contrast, the vaccination of uninfected elders generates lower SARS-CoV-2-specific IgG antibodies, as other studies have already suggested [9, 10, 12, 13] , and these antibodies show lower neutralization capacity is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint population. Therefore, previously infected elders would not benefit from an additional vaccine dose at this time. Additional studies might be required to assess the durability of plasma neutralization capacity in infected elders compared to the younger population.

Even though an assessment of the immune response several months after vaccination has been performed, our study has some limitations. First, the relatively small number of participants, especially for the uninfected elder group, which was unexpectedly low. While 64% of the cohort tested positive by PCR in massive tests screenings during outbreaks, SARS-CoV-2 serologic test revealed that 84% of residents suffered from COVID-19. In addition, we did not assess specific SARS-CoV-2 cellular responses before and after vaccination, which could also be used as a correlate of protection [28] .

Further follow-up of the immune responses, as well as registration of breakthrough infections in COVID-19-uninfected residents from LTCF will allow to define the immune correlate of protection in this frail and vulnerable population. To this purpose, determination of the quality of humoral immune response, using functional neutralization assays, is necessary in the population older than 65 years. Taken together, our results suggest that only the uninfectedresidents, who do not develop adequate immune responses, will clearly benefit from a booster vaccine dose; an adapted vaccination calendar would be necessary to respond to the immune needs of this vulnerable population. Importantly, hybrid immunity seems to be active in elders and can be relevant to design vaccine boosting campaigns. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint at: https://www.ssrn.com/abstract=3937557. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint Tables   Table 1: Descriptive table of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.18.21266502 doi: medRxiv preprint

Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications

Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain

Clinical characteristics of COVID-19 in older adults . A retrospective study in long-term nursing homes in Catalonia

Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme : long-term care facilities Purpose , aim and scope of this activity Changes in version 2 Primary objectives Methods Inclusion criteria for long-term care faci

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents

Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study

Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging

Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection Edwards

Proposals for enhanced health risk assessment and stratification in an integrated care scenario

Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: Prospective cohort study

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors

Hybrid immunity. Science

Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

COVID-19 mRNA Based Vaccine Immune-Response Assessment for Public Health Decision